kp-1461 and HIV-Infections

kp-1461 has been researched along with HIV-Infections* in 4 studies

Trials

1 trial(s) available for kp-1461 and HIV-Infections

ArticleYear
Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.
    PloS one, 2011, Jan-14, Volume: 6, Issue:1

    The deoxycytidine analog KP1212, and its prodrug KP1461, are prototypes of a new class of antiretroviral drugs designed to increase viral mutation rates, with the goal of eventually causing the collapse of the viral population. Here we present an extensive analysis of viral sequences from HIV-1 infected volunteers from the first "mechanism validation" phase II clinical trial of a mutagenic base analog in which individuals previously treated with antiviral drugs received 1600 mg of KP1461 twice per day for 124 days. Plasma viral loads were not reduced, and overall levels of viral mutation were not increased during this short-term study, however, the mutation spectrum of HIV was altered. A large number (N = 105 per sample) of sequences were analyzed, each derived from individual HIV-1 RNA templates, after 0, 56 and 124 days of therapy from 10 treated and 10 untreated control individuals (>7.1 million base pairs of unique viral templates were sequenced). We found that private mutations, those not found in more than one viral sequence and likely to have occurred in the most recent rounds of replication, increased in treated individuals relative to controls after 56 (p = 0.038) and 124 (p = 0.002) days of drug treatment. The spectrum of mutations observed in the treated group showed an excess of A to G and G to A mutations (p = 0.01), and to a lesser extent T to C and C to T mutations (p = 0.09), as predicted by the mechanism of action of the drug. These results validate the proposed mechanism of action in humans and should spur development of this novel antiretroviral approach.

    Topics: Anti-HIV Agents; DNA Mutational Analysis; Genome, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nucleosides; Viral Load

2011

Other Studies

3 other study(ies) available for kp-1461 and HIV-Infections

ArticleYear
Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:2

    Treatment of HIV infection with conventional antiretroviral therapy (ART) is a lifelong challenge with significant long-term risks of adverse events and treatment failure-induced HIV resistance being major concerns. One potential alternative to standard treatment is the use of viral decay accelerators, antiviral agents that theoretically can drive the rate of viral mutation beyond the compensatory capacity of the virus, thereby inducing viral extinction. One such drug, KP-1461, was tested in a population of HIV-infected persons not receiving ART to assess the safety, tolerability, and efficacy of the strategy in vivo. Of 24 highly treatment-experienced HIV-infected patients who received at least one dose of KP-1461, 13 completed the planned 4 months of monotherapy. The drug was generally well tolerated; it did not significantly affect either HIV viral load or CD4 lymphocyte count over the period of dosing. Pharmacokinetic sampling suggested adequate drug exposure was achieved. There were no new mutations induced by KP-1461 that changed viral susceptibility to standard antiretroviral agents. After the study was completed, analysis of more than 7 million base pairs of HIV samples from study patients and controls demonstrated changes in the pattern of viral mutations that differed significantly from what would be encountered naturally. The identified alterations were consistent with an effect resulting from KP-1461's proposed mechanism of action. These findings suggest that the novel antiretroviral approach illustrated by this study should be further investigated, particularly given the relatively good tolerability and the demonstrated excellent safety in this limited cohort study.

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Male; Middle Aged; Mutation; Nucleosides; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load

2013
Novel anti-HIV agent enters Phase IIa clinical trial.
    Expert review of anti-infective therapy, 2007, Volume: 5, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; HIV Infections; Humans; Nucleosides

2007
KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
    Antiviral research, 2005, Volume: 67, Issue:1

    We report the activities of a novel nucleoside analog against HIV. This nucleoside (KP-1212) is not a chain terminator but exerts its antiviral effects via mutagenesis of the viral genome. Serial passaging of HIV in the presence of KP-1212 causes an increase in the mutation rate of the virus leading to viral ablation. HIV strains resistant to KP-1212 have not yet been isolated. Quite to the contrary, virus treated with KP-1212 exhibited an increased sensitivity not only to KP-1212 but also to another nucleoside reverse transcriptase inhibitor (NRTI), zidovudine. HIV strains resistant to other NRTIs (e.g. zidovudine, lamivudine, stavudine, abacavir, etc.) exhibited no cross-resistance towards KP-1212. Multiple assays confirmed that KP-1212 has a favorable (low) genotoxicity profile when compared to some approved antiviral nucleosides. In addition, KP-1212 is not toxic to mitochondria nor does it exhibit any inhibitory effects on mitochondrial DNA synthesis.

    Topics: Animals; Anti-HIV Agents; Azacitidine; Cell Line; Cricetinae; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Nucleosides; Reverse Transcriptase Inhibitors; Zidovudine

2005